Article Versions Notes

Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T, Tanabe Y, Ishimori A, Matsuno K, Abe S, et al. Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules. 2023; 13(3):538. https://doi.org/10.3390/biom13030538

Sandhu, Yuuki, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, and et al. 2023. "Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma" Biomolecules 13, no. 3: 538. https://doi.org/10.3390/biom13030538

Sandhu, Y., Harada, N., Sasano, H., Harada, S., Ueda, S., Takeshige, T., Tanabe, Y., Ishimori, A., Matsuno, K., Abe, S., Nagaoka, T., Ito, J., Chiba, A., Akiba, H., Atsuta, R., Izuhara, K., Miyake, S., & Takahashi, K. (2023). Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules, 13(3), 538. https://doi.org/10.3390/biom13030538